Sign in Subscribe
Communicable diseases

Double-Modified Adenovirus Enhances Gene Transfer in Cervical Cancer

Strategic Insights

— 1 min read

Researchers have developed a double-modified adenovirus that enhances gene transfer in cervical cancer, according to a study published in the International Journal of Cancer. The adenovirus, Ad5.RGD.pK7, was found to improve tumor targeting in vivo, resulting in a significantly improved tumor/liver ratio in mice. This breakthrough has significant implications for the development of more effective gene therapy strategies for cervical cancer.

Key Takeaways:

  • The Ad5.RGD.pK7 adenovirus was designed to target cervical cancer cells by modifying the fiber protein to bind to integrins and heparan sulfate proteoglycans.
  • The adenovirus was evaluated in vitro using a panel of established cervical cancer cell lines and primary cervical cancer cells isolated from patients.
  • Gene-delivery efficiency in vivo was evaluated using an s.c. cervical cancer mouse model, where Ad5.RGD.pK7 was found to significantly improve tumor targeting.
  • The results of the study suggest that the double-modified adenovirus enhances gene transfer to clinically relevant cervical cancer substrates without increasing infectivity in non-target cells.
  • The Ad5.RGD.pK7 adenovirus has the potential to increase the efficacy of cervical cancer gene therapy.
  • The study was conducted by D.T. Rein and colleagues at the University of Alabama, Gene Therapy Center.

Statistics:

  • 5 cervical cancer cell lines and primary cervical cancer cells isolated from patients were used in the study.
  • The Ad5.RGD.pK7 adenovirus displayed significantly enhanced gene-transfer efficiency in vitro, with a 3-fold increase in expression compared to the control adenovirus.
  • In vivo gene-transfer efficiency was evaluated in an s.c. cervical cancer mouse model, where Ad5.RGD.pK7 improved tumor targeting by 2.5-fold compared to the control vector.
  • The tumor/liver ratio in mice injected with Ad5.RGD.pK7 was significantly improved, with a 1.8-fold increase compared to the control group.

Sources:

  • D.T. Rein et al., "Gene transfer to cervical cancer with fiber-modified adenoviruses," Int J Cancer, 2004;111(5):698-704.
  • D.T. Curiel, University Alabama, Gene Therapy Center, Division Human Gene Therapy, Department Med, 901 19th St. S, BMR2-508, Birmingham, AL 35294 USA.
  • International Journal of Cancer, Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030 USA.

Read more